Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Regeneron (IT:1REGN)
MILAN:1REGN
Holding IT:1REGN?
Track your performance easily
1REGN Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€669.80 - €1,083.50
Previous Close€679.2
Volume0.00
Average Volume (3M)5.00
Market Cap
€75.09B
Enterprise Value€68.34B
Total Cash (Recent Filing)$9.80B
Total Debt (Recent Filing)$2.70B
Price to Earnings (P/E)18.2
BetaN/A
Next Earnings
Jan 31, 2025EPS Estimate
€10.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)37.29
Shares Outstanding109,889,531
10 Day Avg. Volume15
30 Day Avg. Volume5
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)2.55
Price to Sales (P/S)5.62
Price to Cash Flow (P/CF)15.10
P/FCF Ratio18.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.94
Enterprise Value/Gross Profit6.05
Enterprise Value/Ebitda12.42
Forecast
1Y Price Target
€1,059.23Price Target Upside55.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering22
Regeneron News
PremiumMarket News
SPY ETF Update, 12/19/2024 
PremiumMarket News
QQQ ETF Update, 12/18/2024 
PremiumMarket News
VOO ETF Update, 12/17/2024 
PremiumMarket News
SPY ETF Update, 12/16/2024 PremiumMarket News
VOO ETF Update, 12/13/2024 
PremiumMarket News
QQQ ETF Update, 12/12/2024Bulls Say, Bears Say
Bulls Say
Market PositionThe Federal Circuit is likely to uphold the preliminary injunctions against biosimilar competitors to Regeneron's Eylea, protecting its market position.
Product GrowthDupixent is expected to continue outperforming with its upcoming launch in Chronic obstructive pulmonary disease and continued dominance in Atopic dermatitis.
Research And DevelopmentRegeneron's pipeline includes multiple programs with candidates pushing efficacy boundaries and offering potentially safer profiles.
Bears Say
Legal ChallengesAmgen is perceived to have a stronger case in its appeal regarding its Eylea biosimilar, which poses a potential risk for Regeneron.
Market CompetitionEylea franchise sales have been significantly cut for upcoming years, reflecting a challenging market environment.
Product PerformanceEylea HD's launch has underperformed compared to the competitor Vabysmo's matched-quarter revenues.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.95% Insiders
33.95% Mutual Funds
19.67% Other Institutional Investors
19.61% Public Companies and
Individual Investors
1REGN FAQ
What was Regeneron’s price range in the past 12 months?
Regeneron lowest stock price was €669.80 and its highest was €1083.50 in the past 12 months.
What is Regeneron’s market cap?
Currently, no data Available
When is Regeneron’s upcoming earnings report date?
Regeneron’s upcoming earnings report date is Jan 31, 2025 which is in 41 days.
How were Regeneron’s earnings last quarter?
Regeneron released its earnings results on Oct 31, 2024. The company reported €11.864 earnings per share for the quarter, beating the consensus estimate of €11.136 by €0.728.
Is Regeneron overvalued?
According to Wall Street analysts Regeneron’s price is currently Undervalued.
Does Regeneron pay dividends?
Regeneron does not currently pay dividends.
What is Regeneron’s EPS estimate?
Regeneron’s EPS estimate is €10.76.
How many shares outstanding does Regeneron have?
Regeneron has 108,072,390 shares outstanding.
What happened to Regeneron’s price movement after its last earnings report?
Regeneron reported an EPS of €11.864 in its last earnings report, beating expectations of €11.136. Following the earnings report the stock price went down -10.387%.
Which hedge fund is a major shareholder of Regeneron?
Among the largest hedge funds holding Regeneron’s share is Dodge & Cox. It holds Regeneron’s shares valued at 2B.
---
Regeneron Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€1,059.23 (55.63% Upside)
€1,059.23 (55.63% Upside)
Blogger Sentiment
Bullish
IT:1REGN Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.51%
12-Months-Change
Fundamentals
Return on Equity
17.17%
Trailing 12-Months
Asset Growth
16.41%
Trailing 12-Months
Company Description
Regeneron
Founded in 1988, Regeneron Pharmaceuticals, Inc. is a New York-based biotechnology company, which discovers, develops, manufactures, and commercializes medicines for the treatment of various medical conditions. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP.
---
1REGN Company Deck
---
1REGN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive outlook driven by strong revenue growth and successful product performances, particularly Dupixent and EYLEA HD. However, there are challenges due to market competition and pricing pressures. Overall, the sentiment is cautiously optimistic, with significant growth opportunities anticipated in 2025.Read More>---
1REGN Revenue Breakdown
44.87% EYLEA - U.S.
28.97% Sanofi
11.34% Bayer
4.11% Libtayo - U.S.
10.72% Other
---
1REGN Stock 12 Month Forecast
Average Price Target
€1,059.23
▲(55.63% Upside)
Technical Analysis
Regeneron
―
Amgen
―
BioMarin Pharmaceutical
―
Gilead Sciences
―
Vertex Pharmaceuticals
―
Best Analysts Covering 1REGN
1 Year
1 Year Success Rate
29/42 ratings generated profit
1 Year Average Return
+17.76%
reiterated a buy rating 12 days ago
Copying Christopher Raymond's trades and holding each position for 1 Year would result in 69.05% of your transactions generating a profit, with an average return of +17.76% per trade.
---